Swiss pharmaceutical giant Roche has unveiled plans to invest an eye-watering $50 billion (£40.3 billion) into the United States over the next five years, signalling a clear response to the mounting pressure of tariffs imposed by President Donald Trump’s administration. The investment, one of the largest by any foreign pharmaceutical company in recent years, is expected to generate over 12,000 jobs across key sectors such as manufacturing, research and construction. This bold move is being interpreted as a defensive measure to protect Roche’s foothold in the lucrative U.S. market amid increasing trade tensions between Switzerland and Washington.  Central to this announcement is the establishment of state-of-the-art facilities dedicated to the production of gene therapy treatments, continuous glucose monitors, and weight-loss medicines. Roche’s forthcoming factory in Pennsylvania will focus on advanced gene therapy, potentially transforming how chronic illnesses are treated. Meanwhile, ...